Nathan Downie
Corporate Officer
Direct Line: 0151 643 5334
Email: foirequests.nhswirralccg@nhs.net

Date: 14th May 2018

Our Ref: ID 1087

NHS Wirral Clinical Commissioning Group
Old Market House
Hamilton Street
Birkenhead
Wirral
CH41 5AL
Tel: 0151 651 0011

Re: Freedom of Information Request

Thank you for your request for information made under the Freedom of Information Act 2000 which was received into this office on 19th April 2018.

You Asked for:

1. Do you have local clinical pathways or standard operating procedures (SOPs) for the use of MabThera? If so are you able to share these? For instance, is one cycle of MabThera intravenous (IV) always used before initiating the patients on MabThera subcutaneous (SC) in oncology indications?

2. Number of patients treated* using MabThera subcutaneous versus MabThera intravenous in oncology indications between 2016-2018, if only partial data is available please indicate the timeframe the data refers to:

Oncology		
Financial Year	Number of patients treated using **MabThera Intravenous** *(if possible, please provide number of patients excluding those who were switched to MabThera subcutaneous)*	Number of patients treated using **MabThera Subcutaneous**
FY 2016-17		
FY 2017-18		

**if number of patients treated is not available please provide information in units that you have available (e.g. vials, preparations…)*

3. Total number of patients treated* with MabThera (intravenous and subcutaneous) vs Rixathon vs Truxima in oncology and rheumatology indications between 2016-2018, if only partial data is available please indicate the timeframe the data refers to:

Financial Year	Drug	Number of patients treated in Oncology	Number of patients treated in Rheumatology
FY 2016-17	MabThera		
	Truxima		
	Rixathon		
FY 2017-18	MabThera		
	Truxima		
	Rixathon		

**if number of patients treated is not available please provide information in units that you have available (e.g. vials, preparations…)*

4. Do you have local clinical pathways or standard operating procedures (SOPs) for the initiation of new patient treatment regimens? If so are you able to share these?

5. Specifically, are new patients directly prescribed biosimilar rituximab (i.e. Truxima or Rixathon) instead of MabThera?

6. Are existing patients being switched from MabThera intravenous to biosimilar rituximab (i.e. Truxima or Rixathon)? If so is there a set point in their treatment pathway when patients are switched and how is this managed?

7. Are any existing patients being switched from MabThera subcutaneous to biosimilar rituximab (i.e. Truxima or Rixathon)? If so is there a set point in their treatment pathway when patients are switched and how is this managed?

8. Number of patients treated* using rituximab biosimilars (Truxima and Rixathon) instead of MabThera (intravenous and subcutaneous) between 2016-2018, if only partial data is available please indicate the timeframe the data refers to:

Financial Year	Drug	Oncology		Rheumatology	
		New patients treated directly with the biosimilar instead of MabThera	Existing patients switched from MabThera to the biosimlar	New patients treated directly with the biosimilar instead of MabThera	Existing patients switched from MabThera to the biosimlar
FY 2016-17	Truxima				
	Rixathon				
FY 2017-18	Truxima				
	Rixathon				

**if number of patients treated is not available please provide information in units that you have available (e.g. vials, preparations…)*

9. As an organisation, are you aware of any financial savings made by using biosimilar rituximab (i.e. Truxima or Rixathon) vs MabThera between 2017-2018, if only partial data

is available please indicate the timeframe the data refers to and the methods used to calculate the financial savings.

Year	**Scheme** *(e.g. discounting, gainshare…)*	**Approximate saving (£)**

10. Please provide information on the current contracts for Truxima, Rixathon, MabThera intravenous (IV) or subcutaneous (SC):

Drug	**ontract value (£)***	**Volume of contract** (number of vials)	**Is price tiered by volume?** (Yes/No)	**Length of contract**		**Renewal frequency**	**Services included**	
				Date o contract nitiation	**Date of contract expiry**		**Yes/No**	**Which services** *(e.g. biosimilar education, patient support program…)*
Rixathon								
Truxima								
MabThera IV								
MabThera SC								

**if the total contract value is not available, please provide the price range for each drug*

11. Related to question 10, if contracts are tiered by volume, could you please provide the thresholds for each tier and what is the price percentage difference between tiers?

Our Response:

1) The local clinical pathways or standard operating procedures (SOPs) for the use of MabThera that NHS Wirral Clinical Commissioning Group (CCG) has is for Rheumatoid Arthritis (attached for your information). The provider hospital (Wirral University Teaching Hospital NHS Foundation Trust) and local cancer centre (Clatterbridge Cancer Care Centre) will have further pathways and standard operating procedures. I have included their contact details within this letter should you wish to contact them direct to request this further information.

2) NHS Wirral CCG does not hold this information.

3) NHS Wirral CCG does not hold this information.

4) Please see response to question 1.

5 – 11) NHS Wirral CCG does not hold this information.

For further information, as detailed above, I have included the contact details for the two provider organisations below:

The Clatterbridge Cancer Centre NHS Foundation Trust - https://www.clatterbridgecc.nhs.uk/about-centre/access-to-information/freedom-information-foi

Wirral University Teaching Hospital NHS Foundation Trust – wih-tr.AccessToInformationOffice@nhs.net

We hope this information is useful, however if you require any further information please do not hesitate to contact a member of the Corporate Affairs Team (contact details at the top of this letter)

Yours sincerely

Re- Use of Information